Literature DB >> 11421995

Interim analyses and sequential designs in phase III studies.

S Todd1, A Whitehead, N Stallard, J Whitehead.   

Abstract

Recruitment of patients to a clinical trial usually occurs over a period of time, resulting in the steady accumulation of data throughout the trial's duration. Yet, according to traditional statistical methods, the sample size of the trial should be determined in advance, and data collected on all subjects before analysis proceeds. For ethical and economic reasons, the technique of sequential testing has been developed to enable the examination of data at a series of interim analyses. The aim is to stop recruitment to the study as soon as there is sufficient evidence to reach a firm conclusion. In this paper we present the advantages and disadvantages of conducting interim analyses in phase III clinical trials, together with the key steps to enable the successful implementation of sequential methods in this setting. Examples are given of completed trials, which have been carried out sequentially, and references to relevant literature and software are provided.

Entities:  

Mesh:

Year:  2001        PMID: 11421995      PMCID: PMC2014474          DOI: 10.1046/j.1365-2125.2001.01382.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  9 in total

Review 1.  A unified theory for sequential clinical trials.

Authors:  J Whitehead
Journal:  Stat Med       Date:  1999 Sep 15-30       Impact factor: 2.373

2.  On being the statistician on a Data and Safety Monitoring Board.

Authors:  J Whitehead
Journal:  Stat Med       Date:  1999-12-30       Impact factor: 2.373

Review 3.  The management of interim analyses in drug development.

Authors:  K M Facey; J A Lewis
Journal:  Stat Med       Date:  1998 Aug 15-30       Impact factor: 2.373

4.  Corticosteroids prevent early deterioration in patients with moderately severe Pneumocystis carinii pneumonia and the acquired immunodeficiency syndrome (AIDS)

Authors:  J S Montaner; L M Lawson; N Levitt; A Belzberg; M T Schechter; J Ruedy
Journal:  Ann Intern Med       Date:  1990-07-01       Impact factor: 25.391

5.  Approximately optimal one-parameter boundaries for group sequential trials.

Authors:  S K Wang; A A Tsiatis
Journal:  Biometrics       Date:  1987-03       Impact factor: 2.571

6.  Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators.

Authors:  A J Moss; W J Hall; D S Cannom; J P Daubert; S L Higgins; H Klein; J H Levine; S Saksena; A L Waldo; D Wilber; M W Brown; M Heo
Journal:  N Engl J Med       Date:  1996-12-26       Impact factor: 91.245

7.  A multiple testing procedure for clinical trials.

Authors:  P C O'Brien; T R Fleming
Journal:  Biometrics       Date:  1979-09       Impact factor: 2.571

8.  Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Medical Research Council Renal Cancer Collaborators.

Authors: 
Journal:  Lancet       Date:  1999-01-02       Impact factor: 79.321

9.  Efficacy and safety of oral sildenafil (Viagra) in men with erectile dysfunction caused by spinal cord injury.

Authors:  F A Derry; W W Dinsmore; M Fraser; B P Gardner; C A Glass; M C Maytom; M D Smith
Journal:  Neurology       Date:  1998-12       Impact factor: 9.910

  9 in total
  9 in total

Review 1.  Learning from previous responses in phase I dose-escalation studies.

Authors:  J Whitehead; Y Zhou; N Stallard; S Todd; A Whitehead
Journal:  Br J Clin Pharmacol       Date:  2001-07       Impact factor: 4.335

Review 2.  Stopping rules for phase II studies.

Authors:  N Stallard; J Whitehead; S Todd; A Whitehead
Journal:  Br J Clin Pharmacol       Date:  2001-06       Impact factor: 4.335

Review 3.  Medications development for the treatment of alcohol use disorder: insights into the predictive value of animal and human laboratory models.

Authors:  Megan M Yardley; Lara A Ray
Journal:  Addict Biol       Date:  2016-02-01       Impact factor: 4.280

4.  Is Implant Coating With Tyrosol- and Antibiotic-loaded Hydrogel Effective in Reducing Cutibacterium (Propionibacterium) acnes Biofilm Formation? A Preliminary In Vitro Study.

Authors:  Konstantinos Tsikopoulos; Alessandro Bidossi; Lorenzo Drago; Daniil R Petrenyov; Panagiotis Givissis; Dimitris Mavridis; Paraskevi Papaioannidou
Journal:  Clin Orthop Relat Res       Date:  2019-07       Impact factor: 4.176

5.  Model-Based Adaptive Optimal Design (MBAOD) Improves Combination Dose Finding Designs: an Example in Oncology.

Authors:  Philippe B Pierrillas; Sylvain Fouliard; Marylore Chenel; Andrew C Hooker; Lena E Friberg; Mats O Karlsson
Journal:  AAPS J       Date:  2018-03-07       Impact factor: 4.009

6.  The differential effects of core stabilization exercise regime and conventional physiotherapy regime on postural control parameters during perturbation in patients with movement and control impairment chronic low back pain.

Authors:  Ramprasad Muthukrishnan; Shweta D Shenoy; Sandhu S Jaspal; Shankara Nellikunja; Svetlana Fernandes
Journal:  Sports Med Arthrosc Rehabil Ther Technol       Date:  2010-05-31

7.  Planning and monitoring of placebo-controlled survival trials: comparison of the triangular test with usual interim analyses methods.

Authors:  Jean-Sébastien Hulot; Michel Cucherat; Andrew Charlesworth; Dirk J Van Veldhuisen; Jean-Christophe Corvol; Alain Mallet; Jean-Pierre Boissel; John Hampton; Philippe Lechat
Journal:  Br J Clin Pharmacol       Date:  2003-03       Impact factor: 4.335

8.  Model-Based Assessment of Alternative Study Designs in Pediatric Trials. Part I: Frequentist Approaches.

Authors:  G Smania; P Baiardi; A Ceci; P Magni; M Cella
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2016-06-01

9.  Effects of dose change on the success of clinical trials.

Authors:  Guogen Shan; Aaron Ritter; Justin Miller; Charles Bernick
Journal:  Contemp Clin Trials Commun       Date:  2022-09-05
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.